FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2336791877> ?p ?o ?g. }

• W2336791877 endingPage "8959" @default.
• W2336791877 startingPage "8951" @default.
• W2336791877 abstract "Human CD8+ cytotoxic T lymphocytes can mediate tumor regression in melanoma through the specific recognition of HLA-restricted peptides. Because of the relatively weak affinity of most anti-cancer T-cell receptors (TCRs), there is growing emphasis on immunizing melanoma patients with altered peptide ligands in order to induce strong anti-tumor immunity capable of breaking tolerance toward these self-antigens. However, previous studies have shown that these immunogenic designer peptides are not always effective. The melanocyte differentiation protein, glycoprotein 100 (gp100), encodes a naturally processed epitope that is an attractive target for melanoma immunotherapies, in particular peptide-based vaccines. Previous studies have shown that substitutions at peptide residue Glu3 have a broad negative impact on polyclonal T-cell responses. Here, we describe the first atomic structure of a natural cognate TCR in complex with this gp100 epitope and highlight the relatively high affinity of the interaction. Alanine scan mutagenesis performed across the gp100280–288 peptide showed that Glu3 was critically important for TCR binding. Unexpectedly, structural analysis demonstrated that the Glu3 → Ala substitution resulted in a molecular switch that was transmitted to adjacent residues, abrogating TCR binding and T-cell recognition. These findings help to clarify the mechanism of T-cell recognition of gp100 during melanoma responses and could direct the development of altered peptides for vaccination. Human CD8+ cytotoxic T lymphocytes can mediate tumor regression in melanoma through the specific recognition of HLA-restricted peptides. Because of the relatively weak affinity of most anti-cancer T-cell receptors (TCRs), there is growing emphasis on immunizing melanoma patients with altered peptide ligands in order to induce strong anti-tumor immunity capable of breaking tolerance toward these self-antigens. However, previous studies have shown that these immunogenic designer peptides are not always effective. The melanocyte differentiation protein, glycoprotein 100 (gp100), encodes a naturally processed epitope that is an attractive target for melanoma immunotherapies, in particular peptide-based vaccines. Previous studies have shown that substitutions at peptide residue Glu3 have a broad negative impact on polyclonal T-cell responses. Here, we describe the first atomic structure of a natural cognate TCR in complex with this gp100 epitope and highlight the relatively high affinity of the interaction. Alanine scan mutagenesis performed across the gp100280–288 peptide showed that Glu3 was critically important for TCR binding. Unexpectedly, structural analysis demonstrated that the Glu3 → Ala substitution resulted in a molecular switch that was transmitted to adjacent residues, abrogating TCR binding and T-cell recognition. These findings help to clarify the mechanism of T-cell recognition of gp100 during melanoma responses and could direct the development of altered peptides for vaccination." @default.
• W2336791877 created "2016-06-24" @default.
• W2336791877 creator A5003273190 @default.
• W2336791877 creator A5008376558 @default.
• W2336791877 creator A5012718447 @default.
• W2336791877 creator A5014641507 @default.
• W2336791877 creator A5016792406 @default.
• W2336791877 creator A5034812246 @default.
• W2336791877 creator A5047132049 @default.
• W2336791877 creator A5057188909 @default.
• W2336791877 creator A5070905694 @default.
• W2336791877 date "2016-04-01" @default.
• W2336791877 modified "2023-09-30" @default.
• W2336791877 title "A Molecular Switch Abrogates Glycoprotein 100 (gp100) T-cell Receptor (TCR) Targeting of a Human Melanoma Antigen" @default.
• W2336791877 cites W1516591549 @default.
• W2336791877 cites W1519533633 @default.
• W2336791877 cites W1594353637 @default.
• W2336791877 cites W1613936157 @default.
• W2336791877 cites W1821172549 @default.
• W2336791877 cites W1852791087 @default.
• W2336791877 cites W1894110757 @default.
• W2336791877 cites W1928212615 @default.
• W2336791877 cites W1969057879 @default.
• W2336791877 cites W1974607230 @default.
• W2336791877 cites W1983806918 @default.
• W2336791877 cites W1986046751 @default.
• W2336791877 cites W1990010910 @default.
• W2336791877 cites W1993446370 @default.
• W2336791877 cites W2001641653 @default.
• W2336791877 cites W2006228719 @default.
• W2336791877 cites W2006922696 @default.
• W2336791877 cites W2014275356 @default.
• W2336791877 cites W2015737099 @default.
• W2336791877 cites W2017672874 @default.
• W2336791877 cites W2032428654 @default.
• W2336791877 cites W2038840577 @default.
• W2336791877 cites W2051700627 @default.
• W2336791877 cites W2062073809 @default.
• W2336791877 cites W2065430316 @default.
• W2336791877 cites W2069113016 @default.
• W2336791877 cites W2076054037 @default.
• W2336791877 cites W2101553545 @default.
• W2336791877 cites W2109810236 @default.
• W2336791877 cites W2116117984 @default.
• W2336791877 cites W2116126292 @default.
• W2336791877 cites W2121487020 @default.
• W2336791877 cites W2127072344 @default.
• W2336791877 cites W2130185552 @default.
• W2336791877 cites W2130542755 @default.
• W2336791877 cites W2132826139 @default.
• W2336791877 cites W2141553969 @default.
• W2336791877 cites W2144081223 @default.
• W2336791877 cites W2146074801 @default.
• W2336791877 cites W2156243354 @default.
• W2336791877 cites W2162959818 @default.
• W2336791877 cites W2163341755 @default.
• W2336791877 cites W4245127498 @default.
• W2336791877 doi "https://doi.org/10.1074/jbc.m115.707414" @default.
• W2336791877 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4861463" @default.
• W2336791877 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26917722" @default.
• W2336791877 hasPublicationYear "2016" @default.
• W2336791877 type Work @default.
• W2336791877 sameAs 2336791877 @default.
• W2336791877 citedByCount "28" @default.
• W2336791877 countsByYear W23367918772017 @default.
• W2336791877 countsByYear W23367918772018 @default.
• W2336791877 countsByYear W23367918772019 @default.
• W2336791877 countsByYear W23367918772020 @default.
• W2336791877 countsByYear W23367918772021 @default.
• W2336791877 countsByYear W23367918772022 @default.
• W2336791877 countsByYear W23367918772023 @default.
• W2336791877 crossrefType "journal-article" @default.
• W2336791877 hasAuthorship W2336791877A5003273190 @default.
• W2336791877 hasAuthorship W2336791877A5008376558 @default.
• W2336791877 hasAuthorship W2336791877A5012718447 @default.
• W2336791877 hasAuthorship W2336791877A5014641507 @default.
• W2336791877 hasAuthorship W2336791877A5016792406 @default.
• W2336791877 hasAuthorship W2336791877A5034812246 @default.
• W2336791877 hasAuthorship W2336791877A5047132049 @default.
• W2336791877 hasAuthorship W2336791877A5057188909 @default.
• W2336791877 hasAuthorship W2336791877A5070905694 @default.
• W2336791877 hasBestOaLocation W23367918771 @default.
• W2336791877 hasConcept C147483822 @default.
• W2336791877 hasConcept C153911025 @default.
• W2336791877 hasConcept C154317977 @default.
• W2336791877 hasConcept C167672396 @default.
• W2336791877 hasConcept C19317047 @default.
• W2336791877 hasConcept C195616568 @default.
• W2336791877 hasConcept C202751555 @default.
• W2336791877 hasConcept C203014093 @default.
• W2336791877 hasConcept C207936829 @default.
• W2336791877 hasConcept C2776090121 @default.
• W2336791877 hasConcept C2777701055 @default.
• W2336791877 hasConcept C2780674031 @default.
• W2336791877 hasConcept C502942594 @default.
• W2336791877 hasConcept C55493867 @default.
• W2336791877 hasConcept C86803240 @default.
• W2336791877 hasConcept C8891405 @default.

• next